Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD, inotuzumab ozogamicin, and blinatumomab yields rapid and deep MRD-negativity and safety among patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia, according to a retrospective...
Dose-dense mini-hyper-CVD,...